Videos

The signs and symptoms leading a pediatrician to a diagnosis of spinal muscular atrophy (SMA) are discussed.

Key opinion leaders discuss pharmacotherapeutic options for the management of narcolepsy symptoms and examine the safety and efficacy of potential treatments.

Experts in neurology discuss the goals of treatment and consider behavioral approaches to the management of narcolepsy and idiopathic hypersomnia including naps and exposure to sunlight.

The president of the Americas Committee for Treatment and Research in MS shared his perspective on the impact of COVID and the top talks at the ACTRIMS Forum 2021.

The chief scientific officer of the Parkinson’s Foundation discussed the “PD GENEration” study that offers genetic testing and counseling to 15,000 people with Parkinson disease.

The PhD candidate at the neuroimmunology laboratory at Memorial University of Newfoundland discussed the potential of interleukin-1 receptor antagonist as a biomarker in MS disability as well as a therapeutic target.

Neurology News Network for the week ending March 20, 2021.

Signs and symptoms to help determine a diagnosis of hereditary ATTR.

A discussion on understanding the disparities of race and gender in hereditary ATTR amyloidosis.

The neurologist from Massachusetts General Hospital discussed when to prescribe disease-modifying therapy and some challenges in caring for patients with RIS.

Episode 7 of the AUPN Leadership Minute features Donald S. Higgins Jr., MD, of the VHA; and Justin C. McArthur, MBBS, MPH, of Johns Hopkins University. [WATCH TIME: 4 minutes]

Diana Castro, M.D., discusses newborn screening for spinal muscular atrophy (SMA) and suggests how to care for patients after the results are received.

Early recognition and referral of a patient with suspected spinal muscular atrophy (SMA) to a neurologist.

An overview of the criteria used to diagnose relapsing-remitting multiple sclerosis when it converts to secondary progressive multiple sclerosis.

A panel of experts led by Bruce Cree, MD, highlight the clinical subtypes of multiple sclerosis including presentation and prevalence.

The fellow of autoimmune neurology at Massachusetts General Hospital discussed the need for follow-up with patients long-term after TNFα inhibitor treatment.

The duo from Montefiore Medical Center discussed how the advancement of technology has benefitted diagnosing epilepsy and classifying seizures in newborns.

A panel of healthcare professionals and patient advocates with migraine recognize the social stigma associated with the condition despite its prevalence in the community.

Philippa Cheetham, MD, and Jill Dehlin, RN, comment on the severity of migraine attacks and concerns that migraines may trigger more series events.

The executive vice president and chief research officer of the MDA offered her perspective on the ongoing conversations about and impact of the pandemic on the care of patients with muscular dystrophies.

The director of the Institute for Health, Health Care Policy, and Aging Research at Rutgers University discussed his recent findings on assessing evidence for dementia care interventions.

The director and founder of the Sleep Centers of Middle Tennessee discussed the gap between sleep apnea prevalence and testing.

Key opinion leaders review reasons for diagnostic delay in narcolepsy including medical and psychiatric comorbidities and discuss diagnostic tools such as sleep diaries, polysomnograms, and cerebrospinal fluid testing.

Expert neurologists discuss the pathophysiology of narcolepsy and examine the role of genetic predisposition, environmental triggers, and immune system involvement.

The postdoctoral researcher at Columbia University discussed her abstract from ACTRIMS Forum 2021 on the associations of MS diagnosis disclosure and concealment with anxiety and depression.

The director of the Montefiore Headache Center discussed the research he would like to see into the treatment, including the potential of combination approaches.

Neurology News Network for the week ending March 13, 2021.

The senior investigator at the National Institutes of Neurological Disorders and Stroke discussed 2 treatments currently being evaluated for use in multiple sclerosis.

Analysis on the prevalence of hereditary ATTR amyloidosis.

Panelists offer an overarching view into hereditary ATTR amyloidosis and differentiate the condition from wild-type ATTR amyloidosis.